Key Insights

Highlights

Success Rate

60% trial completion

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 60/100

Termination Rate

17.4%

4 terminated out of 23 trials

Success Rate

60.0%

-26.6% vs benchmark

Late-Stage Pipeline

9%

2 trials in Phase 3/4

Results Transparency

83%

5 of 6 completed with results

Key Signals

5 with results60% success

Data Visualizations

Phase Distribution

22Total
Not Applicable (3)
Early P 1 (1)
P 1 (7)
P 2 (9)
P 3 (1)
P 4 (1)

Trial Status

Recruiting7
Completed6
Terminated4
Active Not Recruiting2
Not Yet Recruiting2
Suspended1

Trial Success Rate

60.0%

Benchmark: 86.6%

Based on 6 completed trials

Clinical Trials (23)

Showing 20 of 20 trials
NCT07842965Phase 1Not Yet Recruiting

CCR5 Targeting Leronlimab in Combination With Hepatic Arterial Infusion Floxuridine and Systemic Therapy for the Treatment of Colorectal Cancer Liver Metastases, CHAMP Trial

NCT05863195Phase 3Recruiting

Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial

NCT03457948Phase 2CompletedPrimary

Pembrolizumab With Liver-Directed or Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors and Liver Metastases

NCT05791448Phase 1Suspended

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

NCT05039632Phase 1Recruiting

Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies

NCT03203525Phase 1Terminated

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer

NCT04796818Not ApplicableRecruiting

An Investigational Scan (Intravoxel Incoherent Motion Diffusion Weighted Imaging) for the Evaluation of Colorectal Cancer Liver Metastases Treatment Response

NCT02364557Phase 2Completed

Testing Whether Treating Breast Cancer Metastases With Surgery or High-Dose Radiation Improves Survival

NCT03472586Phase 2CompletedPrimary

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

NCT06016855Phase 4Recruiting

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors

NCT02156739Not ApplicableActive Not Recruiting

Contrast-enhanced MRI in Detecting Benign and Malignant Liver Lesions

NCT02626312Phase 1Terminated

Radiation Therapy in Treating Patients With Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function

NCT07612007Phase 2Not Yet Recruiting

HRX215, A First Generation MKK4 Inhibitor Drug, for the Treatment of Patients With Colorectal Liver Metastasis After Undergoing a Portal Vein Embolization

NCT04982653Phase 2Recruiting

Short Stitch Versus Traditional Suture for the Prevention of Incisional Hernia After Open Hepatectomy

NCT04728633Phase 2Active Not RecruitingPrimary

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

NCT02738606Phase 2Terminated

Liver Surgery and Chemotherapy in Treating Patients With Colorectal Cancer With Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery

NCT03844750Phase 2TerminatedPrimary

Preoperative Immunotherapy (Pembrolizumab) for Patients With Colorectal Cancer and Resectable Hepatic Metastases

NCT05040360Phase 2RecruitingPrimary

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

NCT02070549Phase 1Completed

Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction

NCT06449937Not ApplicableRecruiting

Local Liver Treatment for Multi-organ Colorectal Cancer Metastases

Scroll to load more

Research Network

Activity Timeline